<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
"http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<head>
<!-- 2015-11-30 Mon 16:18 -->
<meta  http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta  name="viewport" content="width=device-width, initial-scale=1" />
<title>RSV</title>
<meta  name="generator" content="Org-mode" />
<meta  name="author" content="Abhishek Pandey" />
<style type="text/css">
 <!--/*--><![CDATA[/*><!--*/
  .title  { text-align: center;
             margin-bottom: .2em; }
  .subtitle { text-align: center;
              font-size: medium;
              font-weight: bold;
              margin-top:0; }
  .todo   { font-family: monospace; color: red; }
  .done   { font-family: monospace; color: green; }
  .priority { font-family: monospace; color: orange; }
  .tag    { background-color: #eee; font-family: monospace;
            padding: 2px; font-size: 80%; font-weight: normal; }
  .timestamp { color: #bebebe; }
  .timestamp-kwd { color: #5f9ea0; }
  .org-right  { margin-left: auto; margin-right: 0px;  text-align: right; }
  .org-left   { margin-left: 0px;  margin-right: auto; text-align: left; }
  .org-center { margin-left: auto; margin-right: auto; text-align: center; }
  .underline { text-decoration: underline; }
  #postamble p, #preamble p { font-size: 90%; margin: .2em; }
  p.verse { margin-left: 3%; }
  pre {
    border: 1px solid #ccc;
    box-shadow: 3px 3px 3px #eee;
    padding: 8pt;
    font-family: monospace;
    overflow: auto;
    margin: 1.2em;
  }
  pre.src {
    position: relative;
    overflow: visible;
    padding-top: 1.2em;
  }
  pre.src:before {
    display: none;
    position: absolute;
    background-color: white;
    top: -10px;
    right: 10px;
    padding: 3px;
    border: 1px solid black;
  }
  pre.src:hover:before { display: inline;}
  pre.src-sh:before    { content: 'sh'; }
  pre.src-bash:before  { content: 'sh'; }
  pre.src-emacs-lisp:before { content: 'Emacs Lisp'; }
  pre.src-R:before     { content: 'R'; }
  pre.src-perl:before  { content: 'Perl'; }
  pre.src-java:before  { content: 'Java'; }
  pre.src-sql:before   { content: 'SQL'; }

  table { border-collapse:collapse; }
  caption.t-above { caption-side: top; }
  caption.t-bottom { caption-side: bottom; }
  td, th { vertical-align:top;  }
  th.org-right  { text-align: center;  }
  th.org-left   { text-align: center;   }
  th.org-center { text-align: center; }
  td.org-right  { text-align: right;  }
  td.org-left   { text-align: left;   }
  td.org-center { text-align: center; }
  dt { font-weight: bold; }
  .footpara { display: inline; }
  .footdef  { margin-bottom: 1em; }
  .figure { padding: 1em; }
  .figure p { text-align: center; }
  .inlinetask {
    padding: 10px;
    border: 2px solid gray;
    margin: 10px;
    background: #ffffcc;
  }
  #org-div-home-and-up
   { text-align: right; font-size: 70%; white-space: nowrap; }
  textarea { overflow-x: auto; }
  .linenr { font-size: smaller }
  .code-highlighted { background-color: #ffff00; }
  .org-info-js_info-navigation { border-style: none; }
  #org-info-js_console-label
    { font-size: 10px; font-weight: bold; white-space: nowrap; }
  .org-info-js_search-highlight
    { background-color: #ffff00; color: #000000; font-weight: bold; }
  /*]]>*/-->
</style>
<link rel="stylesheet" type="text/css" href="http://www.pirilampo.org/styles/bigblow/css/htmlize.css"/>
<link rel="stylesheet" type="text/css" href="http://www.pirilampo.org/styles/bigblow/css/bigblow.css"/>
<link rel="stylesheet" type="text/css" href="http://www.pirilampo.org/styles/bigblow/css/hideshow.css"/>
<script type="text/javascript" src="http://www.pirilampo.org/styles/bigblow/js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="http://www.pirilampo.org/styles/bigblow/js/jquery-ui-1.10.2.min.js"></script>
<script type="text/javascript" src="http://www.pirilampo.org/styles/bigblow/js/jquery.localscroll-min.js"></script>
<script type="text/javascript" src="http://www.pirilampo.org/styles/bigblow/js/jquery.scrollTo-1.4.3.1-min.js"></script>
<script type="text/javascript" src="http://www.pirilampo.org/styles/bigblow/js/jquery.zclip.min.js"></script>
<script type="text/javascript" src="http://www.pirilampo.org/styles/bigblow/js/bigblow.js"></script>
<script type="text/javascript" src="http://www.pirilampo.org/styles/bigblow/js/hideshow.js"></script>
<script type="text/javascript">
/*
@licstart  The following is the entire license notice for the
JavaScript code in this tag.

Copyright (C) 2012-2013 Free Software Foundation, Inc.

The JavaScript code in this tag is free software: you can
redistribute it and/or modify it under the terms of the GNU
General Public License (GNU GPL) as published by the Free Software
Foundation, either version 3 of the License, or (at your option)
any later version.  The code is distributed WITHOUT ANY WARRANTY;
without even the implied warranty of MERCHANTABILITY or FITNESS
FOR A PARTICULAR PURPOSE.  See the GNU GPL for more details.

As additional permission under GNU GPL version 3 section 7, you
may distribute non-source (e.g., minimized or compacted) forms of
that code without the copy of the GNU GPL normally required by
section 4, provided you include this license notice and a URL
through which recipients can access the Corresponding Source.


@licend  The above is the entire license notice
for the JavaScript code in this tag.
*/
<!--/*--><![CDATA[/*><!--*/
 function CodeHighlightOn(elem, id)
 {
   var target = document.getElementById(id);
   if(null != target) {
     elem.cacheClassElem = elem.className;
     elem.cacheClassTarget = target.className;
     target.className = "code-highlighted";
     elem.className   = "code-highlighted";
   }
 }
 function CodeHighlightOff(elem, id)
 {
   var target = document.getElementById(id);
   if(elem.cacheClassElem)
     elem.className = elem.cacheClassElem;
   if(elem.cacheClassTarget)
     target.className = elem.cacheClassTarget;
 }
/*]]>*///-->
</script>
</head>
<body>
<div id="content">
<h1 class="title">RSV</h1>



<div id="outline-container-orgheadline1" class="outline-2">
<h2 id="orgheadline1">Analysis requests</h2>
<div class="outline-text-2" id="text-orgheadline1">
<p>
We are going to perform cost-effectiveness of RSV vaccination in the
elderly  by performing following analysis:
</p>
<ul class="org-ul">
<li><p>
Target Population: 65+
</p>
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-left" />

<col  class="org-left" />

<col  class="org-left" />

<col  class="org-left" />
</colgroup>
<thead>
<tr>
<th scope="col" class="org-left">&#xa0;</th>
<th scope="col" class="org-left">Basecase</th>
<th scope="col" class="org-left">Analysis 1</th>
<th scope="col" class="org-left">Analysis 2</th>
<th scope="col" class="org-left">Analysis 3</th>
</tr>
</thead>
<tbody>
<tr>
<td class="org-left">Dose frequency</td>
<td class="org-left">Every year</td>
<td class="org-left">Every 5 years</td>
<td class="org-left">Every 2 years</td>
<td class="org-left">Every year</td>
</tr>

<tr>
<td class="org-left">Vaccine efficacy</td>
<td class="org-left">60%</td>
<td class="org-left">85%</td>
<td class="org-left">60%</td>
<td class="org-left">45%</td>
</tr>
</tbody>
</table></li>
</ul>


<p>
We do analysis for above for following settings:
</p>
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-left" />

<col  class="org-right" />
</colgroup>
<tbody>
<tr>
<td class="org-left">Model</td>
<td class="org-left">Dynamic</td>
<td class="org-right">Static</td>
</tr>

<tr>
<td class="org-left">Viral load reduction</td>
<td class="org-left">None</td>
<td class="org-right">50%</td>
</tr>
</tbody>
</table>

<ul class="org-ul">
<li><p>
Target Population: 65+ with underlying cardiopulmonary disease
</p>
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-left" />

<col  class="org-left" />

<col  class="org-left" />

<col  class="org-left" />
</colgroup>
<thead>
<tr>
<th scope="col" class="org-left">&#xa0;</th>
<th scope="col" class="org-left">Basecase</th>
<th scope="col" class="org-left">Analysis 1</th>
<th scope="col" class="org-left">Analysis 2</th>
<th scope="col" class="org-left">Analysis 3</th>
</tr>
</thead>
<tbody>
<tr>
<td class="org-left">Dose frequency</td>
<td class="org-left">Every year</td>
<td class="org-left">Every 5 years</td>
<td class="org-left">Every 2 years</td>
<td class="org-left">Every year</td>
</tr>

<tr>
<td class="org-left">Vaccine efficacy</td>
<td class="org-left">60%</td>
<td class="org-left">85%</td>
<td class="org-left">60%</td>
<td class="org-left">45%</td>
</tr>
</tbody>
</table>

<p>
We do analysis for above for following settings:
</p>
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-left" />

<col  class="org-right" />
</colgroup>
<tbody>
<tr>
<td class="org-left">Model</td>
<td class="org-left">-</td>
<td class="org-right">Static</td>
</tr>

<tr>
<td class="org-left">Viral load reduction</td>
<td class="org-left">None</td>
<td class="org-right">50%</td>
</tr>
</tbody>
</table></li>
</ul>
</div>
</div>


<div id="outline-container-orgheadline2" class="outline-2">
<h2 id="orgheadline2">What we need for analysis ?</h2>
<div class="outline-text-2" id="text-orgheadline2">
<ul class="org-ul">
<li><b>Discount rates:</b> I have assumed it to be 2% for now. What should
I use ? <i>Check out Eunha Shim's paper to see what they used</i></li>

<li><b>Hospitalization:</b> How many people get hospitalized due to RSV
each year? How to get it model/data ?
/</li>
<li><b>RSV deaths:</b> Same problem as Hospitalization.</li>
<li><b>Outpatient Visits:</b> Same problem as Hospitalization.</li>
<li><b>Emergency Visits:</b> Same problem as Hospitalization.</li>
<li><b>Life Expectancy of 65+:</b> For now, I am using 17.1 from <a href="https://paperpile.com/shared/heC27c">Gessner
2000</a>. Get a weighted average for 65+ people.</li>

<li><b>Utilities per measures:</b> For now, I am using some values from <a href="https://paperpile.com/shared/heC27c">Gessner 2000</a>.</li>
<li><b>Duration for each measures:</b> For now, I am using some assumed
values. Need to find better estimates.</li>
<li><b>Case reduction and reduction in outcome measures:</b> How to connect
the reduction in cases to reduction in hospitalizations, deaths,
etc.</li>
<li><b>Costs:</b> Finding costs for the various measures.</li>
</ul>
</div>

<div id="outline-container-orgheadline11" class="outline-3">
<h3 id="orgheadline11">Literature</h3>
<div class="outline-text-3" id="text-orgheadline11">
</div><div id="outline-container-orgheadline3" class="outline-4">
<h4 id="orgheadline3"><a href="https://paperpile.com/shared/IdsMcu">The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly (Gessner 2000 - Vaccine)</a></h4>
<div class="outline-text-4" id="text-orgheadline3">
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-right" />
</colgroup>
<tbody>
<tr>
<td class="org-left">Average life expectancy of  65-year-old, in years</td>
<td class="org-right">17.4</td>
</tr>

<tr>
<td class="org-left">Length of RSV hospitalization, in days</td>
<td class="org-right">14</td>
</tr>

<tr>
<td class="org-left">Length of RSV upper respiratory infection, in days</td>
<td class="org-right">6.6</td>
</tr>

<tr>
<td class="org-left">Length of hospitalization of COPD</td>
<td class="org-right">5.7</td>
</tr>

<tr>
<td class="org-left">Population-based RSV ARI incidence estimate, per 100,000 per year</td>
<td class="org-right">13,000</td>
</tr>

<tr>
<td class="org-left">Proportion of persons with RSV ARI who visit a physician</td>
<td class="org-right">0.45</td>
</tr>

<tr>
<td class="org-left">Incidence of hospitalizations for all pneumonia per 100,000 per year</td>
<td class="org-right">1100</td>
</tr>

<tr>
<td class="org-left">Proportion of pneumonia hospitalizations due to RSV</td>
<td class="org-right">0.040</td>
</tr>

<tr>
<td class="org-left">Proportion of hospitalized persons with RSV ARI who die</td>
<td class="org-right">0.11</td>
</tr>

<tr>
<td class="org-left">Incidence of hospitalization for COPD per 100,000 per year</td>
<td class="org-right">0.0095</td>
</tr>

<tr>
<td class="org-left">Incidence of death due to COPD per 100,000 per year</td>
<td class="org-right">0.0013</td>
</tr>

<tr>
<td class="org-left">Baseline health-related quality of life for 65 years old</td>
<td class="org-right">0.76</td>
</tr>

<tr>
<td class="org-left">Outpatient illness utility</td>
<td class="org-right">0.76</td>
</tr>

<tr>
<td class="org-left">Nursing home utility</td>
<td class="org-right">0.46</td>
</tr>

<tr>
<td class="org-left">Hospitalization</td>
<td class="org-right">0.35</td>
</tr>

<tr>
<td class="org-left">Physician Outpatient visit cost</td>
<td class="org-right">145 (82,245)</td>
</tr>

<tr>
<td class="org-left">Hospitalization for RSV pneumonia</td>
<td class="org-right">7567 (4433,10700)</td>
</tr>

<tr>
<td class="org-left">Hospitalization for COPD</td>
<td class="org-right">4022</td>
</tr>

<tr>
<td class="org-left">Yearly nursing home costs</td>
<td class="org-right">34912</td>
</tr>

<tr>
<td class="org-left">Average future yearly medical costs of persons 65-74</td>
<td class="org-right">5586</td>
</tr>

<tr>
<td class="org-left">Average future yearly medical costs of persons 75-82</td>
<td class="org-right">8097</td>
</tr>
</tbody>
</table>

<ul class="org-ul">
<li>They assumed that vaccine effectiveness to be 80% against
hospitalization and death and 50% against upper respiratory
infection (similar to influenza vaccine effectiveness).</li>
<li>They discounted nursing home admissions and deaths following
RSV-related lower respiratory infection, and nursing home and
future medical costs at 3% for base and best case and at 5% for
the worst case scenario.</li>
<li>They considered two scenarios:
<ol class="org-ol">
<li>Without a 10% vaccine effectiveness against COPD,</li>
<li>With a 10% vaccine effectiveness against COPD</li>
</ol></li>
</ul>
</div>
</div>

<div id="outline-container-orgheadline4" class="outline-4">
<h4 id="orgheadline4"><a href="https://paperpile.com/shared/Km8FUr">Respiratory syncytial virus infection in older persons (Falsey 1998 - Vaccine)</a></h4>
<div class="outline-text-4" id="text-orgheadline4">
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-right" />
</colgroup>
<tbody>
<tr>
<td class="org-left">Rates of RSV pneumonia</td>
<td class="org-right">5-67%</td>
</tr>

<tr>
<td class="org-left">Rates of RSV deaths</td>
<td class="org-right">0-20%</td>
</tr>

<tr>
<td class="org-left">RSV associated hospitalization length in days</td>
<td class="org-right">14</td>
</tr>
</tbody>
</table>
</div>
</div>

<div id="outline-container-orgheadline5" class="outline-4">
<h4 id="orgheadline5"><a href="https://paperpile.com/shared/dhwZ95">Respiratory Syncytial Virus and Influenza A Infections in the Hospitalized Elderly (Falsey et al. 1995 - J.Infect.Dis.)</a></h4>
<div class="outline-text-4" id="text-orgheadline5">
<table border="2" cellspacing="0" cellpadding="6" rules="groups" frame="hsides">


<colgroup>
<col  class="org-left" />

<col  class="org-right" />
</colgroup>
<tbody>
<tr>
<td class="org-left">RSV related death rates</td>
<td class="org-right">10%</td>
</tr>

<tr>
<td class="org-left">Length of hospitalization stay, in days</td>
<td class="org-right">16</td>
</tr>
</tbody>
</table>
</div>
</div>

<div id="outline-container-orgheadline6" class="outline-4">
<h4 id="orgheadline6"><a href="https://paperpile.com/shared/O4vO9r">Mortality Associated With Influenza and Respiratory Syncytial Virus in United States (Thompson et al. 2003 - JAMA)</a></h4>
<div class="outline-text-4" id="text-orgheadline6">
<ul class="org-ul">
<li>This paper has information for elderly people at finer scales, a
lot of it is about influenza related illness (worth a look, if
required).</li>
<li>78% of RSV-associated underlying respiratory and circulatory
deaths occurred among persons age 65 years or older.</li>
</ul>
</div>
</div>

<div id="outline-container-orgheadline7" class="outline-4">
<h4 id="orgheadline7"><a href="https://paperpile.com/shared/O8viIf">Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults (Falsey et al. 2005 - N.Engl.J.Med.)</a></h4>
<div class="outline-text-4" id="text-orgheadline7">
<ul class="org-ul">
<li>Among healthy elderly patients, influenza A infection generated
a greater percentage of office visits/outpatient visits than did
RSV infection (42% vs 17%)</li>
<li>The total number of health care visits (office visits, emergency
room visits and hospitalizations) was similar for the two
viruses.</li>
<li>Overall, RSV infection accounted for 10.6% of hospitalization
for pneumonia, 11.4% for COPD, 5.4% for congestive heart failure
and 7.2% for ashthma.</li>
<li>Combining data for no of discharges from U.S. hospitals of adults
65+ for the diagnose of pneumonia, COPD, congestive heart
failure and asthma from National Center for Health Statistics of
the CDC, in 1999 with their rates, they found that RSV infection
would account for approximately <b>177,525</b> admissions each
year.</li>
<li>Also, based on the death rate for hospitalized patients with RSV
infection (8%), <b>14,000</b> annual deaths would be predicted.</li>
<li>18% of outpatient/office visits made by elderly adults for
respiratory illness during winter were RSV-related.</li>
</ul>
</div>
</div>

<div id="outline-container-orgheadline8" class="outline-4">
<h4 id="orgheadline8"><a href="https://paperpile.com/shared/eIG4oc">RSV vaccine in development: Assessing the potential cost-effectiveness in the Dutch elderly population (Meijboom et al. 2013 - Vaccine)</a></h4>
<div class="outline-text-4" id="text-orgheadline8">
<ul class="org-ul">
<li>They have life expectancies for High and low risk individuals in
age-groups (60-64,65-74,75-84,85+). High risk population was
categorized based on International Classification of Primary
Care (ICPC).</li>
<li>They have utilities of 0.46 for GP visit and 0.35 for
hospitalization. Moreover, they assume that patients experience
the utility for 1 week in case of GP visit and 3 weeks when they
are hospitalized. (Is this right ?).</li>
</ul>
</div>
</div>

<div id="outline-container-orgheadline9" class="outline-4">
<h4 id="orgheadline9"><a href="https://paperpile.com/shared/N6WTUW">Respiratory Syncytial Virus Infection in Elderly Adults (Falsey and Walsh 2005 - Drugs Aging)</a></h4>
<div class="outline-text-4" id="text-orgheadline9">
<p>
Not any different information than others.
</p>
</div>
</div>

<div id="outline-container-orgheadline10" class="outline-4">
<h4 id="orgheadline10"><a href="https://paperpile.com/shared/mgu6Nr">Respiratory Syncytial Virus Pneumonia among the Elderly: An Assessment of Disease Burden Han et al. 1999 - J.Infect.Dis.</a></h4>
</div>
</div>
</div>



<div id="outline-container-orgheadline12" class="outline-2">
<h2 id="orgheadline12">Parameters</h2>
</div>

<div id="outline-container-orgheadline13" class="outline-2">
<h2 id="orgheadline13">With Dan</h2>
</div>
</div>
<div id="postamble" class="status">
<p class="author">Author: Abhishek Pandey</p>
<p class="date">Created: 2015-11-30 Mon 16:18</p>
<p class="validation"><a href="http://validator.w3.org/check?uri=referer">Validate</a></p>
</div>
</body>
</html>
